Is There A Relationship Between Visfatin Level and Type 2 Diabetes Mellitus In Obese And Non Obese Patients?

被引:8
|
作者
El-Shafey, Eid M. [1 ]
El-Naggar, Gamal F. [1 ]
Al-Bedewy, Mohamed M. [2 ]
El-Sorogy, Hesham [3 ]
机构
[1] Tanta Univ, Fac Med, Internal Med Dept, Neprol Div, Tanta, Egypt
[2] Tanta Univ, Fac Med, Internal Med Dept, Tanta, Egypt
[3] Tanta Univ, Fac Med, Clin Pathol Dept, Tanta, Egypt
关键词
Visfatin; Type 2 diabetes mellitus; Obesity;
D O I
10.4172/2155-6156.S11-001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Visfatin is a newly discovered cytokine that is highly expressed in visceral fat with a direct relationship to type 2 diabetes mellitus (T2DM). The present study was conducted to demonstrate the relationship between plasma visfatin level and T2DM whether in obese or non obese patients. Subjects and methods: This prospective study was carried out on 74 subjects divided into 4 groups. Group I: Twenty obese non diabetic patients, Group II: Twenty obese diabetic patients, Group III: Twenty non obese diabetic patients and Group IV: Fourteen age and gender matched apparently healthy subjects to serve as controls. All patients and controls were subjected to full history taking, complete clinical examination, routine laboratory investigations, fasting serum insulin, homeostasis model assessment of insulin resistance (HOMA IR) and serum visfatin level. Results: Serum visfatin level was significantly increased in the obese subjects and in the diabetics with the highest rise in the obese diabetics suggesting that serum visfatin level has a link between obesity and T2DM. Also, there was a significant positive correlation between serum visfatin level and body mass index (BMI), serum insulin & HOMA IR. Conclusion: There may be a possible role of visfatin in the Pathophysiology of insulin resistance, T2DM and obesity.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] Impact of orlistat on fasting hyperglycemia in obese patients with type 2 diabetes mellitus
    Kelley, DE
    OBESITY RESEARCH, 2001, 9 : 188S - 188S
  • [42] Economic Evaluation of Orlistat in Overweight and Obese Patients with Type 2 Diabetes Mellitus
    Andreas Maetzel
    Jörg Ruof
    Melva Covington
    Anne Wolf
    PharmacoEconomics, 2003, 21 : 501 - 512
  • [43] Study of Obstructive Sleep Apnea in Obese Patients with Type 2 Diabetes Mellitus
    Srivastava, G. N.
    Sharma, Mrityunjay
    Singh, S. K.
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2020, 14 (06) : OC06 - OC08
  • [44] Impact of orlistat on fasting hyperglycemia in obese patients with type 2 diabetes mellitus
    Kelley, DE
    DIABETES, 2001, 50 : A439 - A439
  • [45] Heart rate variability in obese patients without and with diabetes mellitus type 2
    Siegelova, J
    Svacinova, H
    Fiser, B
    Dusek, J
    Jancik, J
    Svoboda, L
    Hruby, I
    Soucek, M
    JOURNAL OF HYPERTENSION, 2005, 23 : S102 - S102
  • [46] Assessment of the efficacy of diet therapy in obese patients with type 2 diabetes mellitus
    Kowalcze, Katarzyna
    Starbaa, Agnieszka
    ANNALS OF NUTRITION AND METABOLISM, 2007, 51 : 341 - 341
  • [47] Comparison of insulin sensitivity in patients with insulinoma and obese type 2 diabetes mellitus
    Skrha, J
    Sindelka, G
    Haas, T
    Hilgertova, J
    Justova, V
    HORMONE AND METABOLIC RESEARCH, 1996, 28 (11) : 595 - 598
  • [48] The Impact of Hypoxemia on Nephropathy in Extremely Obese Patients with Type 2 Diabetes Mellitus
    Leong, Wen Bun
    Nolen, Melissa
    Thomas, G. Neil
    Adab, Paymane
    Banerjee, Dev
    Taheri, Shahrad
    JOURNAL OF CLINICAL SLEEP MEDICINE, 2014, 10 (07): : 773 - 778
  • [49] Differences in the insulin counterregulatory hormones between obese and nonobese male patients with type 2 diabetes mellitus
    Rong Huang
    Yujie Bao
    Yuanli Xiong
    Jianhua Ma
    Bo Ding
    Scientific Reports, 15 (1)
  • [50] Correlation between weight loss and improvement of diabetes mellitus among obese type 2 diabetic patients
    Harayama T.
    Yoshida T.
    Yoshioka K.
    Kogure A.
    Sakai R.
    Yasui T.
    Kondo Y.
    Fukui M.
    Hasegawa G.
    Nakamura N.
    Diabetology International, 2013, 4 (2) : 132 - 137